Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.

JAMA oncology - 1 Sept 2015

Héritier Sébastien, Jehanne Mathilde, Leverger Guy, Emile Jean-François, Alvarez Jean-Claude, Haroche Julien, Donadieu Jean

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histiocytosis, Langerhans-Cell
Share to Indoles
Share to Molecular Targeted Therapy
Share to Proto-Oncogene Proteins B-raf

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Remission Induction

Share to Sulfonamides

Share to Tomography, X-Ray Computed

Share to Vemurafenib

Source

Identifiers

PMID: 26180941
DOI: 10.1001/jamaoncol.2015.0736

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.PMID 26180941Read ↗

Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.Semantic proximity Read ↗

Refractory multisystem Langerhans cell histiocytosis in an infant: use of vemurafenib as a therapeutic option.Semantic proximity Read ↗

Early association of Vemurafenib to standard chemotherapy in multisystemic Langerhans cell histiocytosis in a newborn: take the chance for a better outcome?Semantic proximity Read ↗

Targeted Therapy with Vemurafenib in Brazilian Children with Refractory Langerhans Cell Histiocytosis: Two Case Reports and a Comprehensive ReviewSemantic proximity Read ↗

Vemurafenib provides a rapid and robust clinical response in paediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease based on ddPCR using cell-free circulating DNASemantic proximity Read ↗

Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature.Semantic proximity Read ↗

Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.Semantic proximity Read ↗

Cutaneous adverse events in children treated with vemurafenib for refractory BRAFV600E mutated Langerhans cell histiocytosis.Semantic proximity Read ↗

Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study.Semantic proximity Read ↗

BRAF Mutated LCH: Diagnosis and Treatment Challenges - A High-Risk Case Presentation and Discussion.Semantic proximity Read ↗

Failure of salvage vemurafenib therapy for refractory multisystem Langerhans cell histiocytosis with BRAF-V600E mutationSemantic proximity Read ↗

Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.